Safety and Efficacy of TKIs in very Elderly Patients (≥75 Years) with Chronic Myeloid Leukemia.

ABSTRACT:

Background

While the outcomes of chronic phase chronic myeloid leukemia (CP-CML) patients aged over 65 years have been extensively evaluated in real-life experiences, limited data exist for the very elderly population (i.e., aged ≥ 75 years), especially for next-generation tyrosine kinase inhibitors (TKIs). In this retrospective study, we sought to evaluate the safety and efficacy of TKIs in this particular setting of patients.

Methods

We conducted a retrospective analysis of a multicenter cohort of 123 newly diagnosed CP-CML very elderly patients.

Results

The median age at diagnosis was 80 years (range: 75-96). In the first line, 86.1% of patients received imatinib, 7.1% dasatinib, 5.6% nilotinib, and 0.81% received bosutinib. A total of 31 patients (25.2%) switched

SUBMITTER: Costa A 

PROVIDER: S-EPMC10779829 | biostudies-literature | 2024 Jan

REPOSITORIES: biostudies-literature